trending Market Intelligence /marketintelligence/en/news-insights/trending/t99UD-9AATene705_xNDrQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Novartis to not sell 33% stake in Roche

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Novartis to not sell 33% stake in Roche

Novartis AG will not sell its 33% voting stake in Roche Holding AG, which is worth about $14 billion, Reuters reported Oct. 11.

In an interview with Swiss newspaper HandelsZeitung, Chairman Joerg Reinhardt said Novartis decided, after a review, that selling the stake does not make sense.

CEO Joe Jimenez had stated in May 2016 that the company was exploring the disposal of the stake in Roche without a premium, according to the news outlet.

Novartis built up its holdings in Roche between 2001 and 2003 under former Chairman Daniel Vasella in connection with a potential merger.